DIAGNOS Appoints New Chief Operating Officer
January 16 2024 - 10:00AM
Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK)
(OTCQB: DGNOF), a pioneer in early detection of critical health
issues through the use of Artificial Intelligence (AI)
technologies, is pleased to announce the appointment of Mr.
Yves-Stéphane Couture as Chief Operating Officer. As part of his
duties, Mr. Couture will be responsible for the continuous
development of our flagship product CARA as well as its
commercialization worldwide.
Mr. Couture joined DIAGNOS in 2017. Since then,
he has been a key asset in the development of AI-based solutions
used by optometrists and ophthalmologists to detect and classify
multiple illnesses through the analysis of fundus pictures as well
as retina scans. Yves-Stéphane strongly believes that AI-based
solutions is key to solving some of the most important challenges
facing healthcare providers in the delivery of care to patients.
“By his actions, Yves-Stéphane has shown total dedication to the
success of the Corporation and, on behalf of our employees and
directors, I wish him the best in his continued efforts to grow our
revenues,” said Mr. André Larente, President of DIAGNOS. Mr.
Couture’s new role is effective January 15, 2024.
Prior to joining DIAGNOS, Mr. Couture led sales
and implementation teams with large IT and telecommunication
companies, such as Alcatel-Lucent and Teleglobe, where he was in
charge of commercializing and implementing complex infrastructure
solutions for health care providers and hospitals. Mr. Couture
holds a Bachelor degree in administration from the University of
Sherbrooke where he also received a master degree in marketing.
The board of directors of the Corporation has
approved a grant of 100,000 stock options to Mr. Couture.
The date of the grant is January 15, 2024. Stock options vest at
50% per year, commencing with the first anniversary of the grant.
The exercise price of the stock options has been established at
$0.41 per common share. The expiry date to which the stock options
can be exercised has been fixed to January 15, 2029.
All monies quoted in this press release shall be
stated and paid in lawful money of Canada.
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. Additional information is available
at www.diagnos.ca and http://www.sedar.com.
This press release
contains forward-looking information. We cannot guarantee that the
forward-looking information mentioned will prove to be accurate, as
there may be a significant discrepancy between actual results or
future events and those mentioned in this statement. DIAGNOS
disclaims any intention or obligation to publicly update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise. The forward-looking
information contained in this press release is expressly covered by
this caution.
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For further information, please contact;
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
Email: alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024